Patent details
EP1699782 Title: MALEATE SALTS OF A QUINAZOLINE DERIVATIVE USEFUL AS AN ANTIANGIOGENIC AGENT
Basic Information
- Publication number:
- EP1699782
- PCT Application Number:
- PCT/GB/2004/005359
- Type:
- European Patent Granted for LU
- Legal Status:
- Expired
- Application number:
- EP048061592
- PCT Publication Number:
- WO/2005/061488
- First applicant's nationality:
- Translation Language:
- EPO Publication Language:
- English
- English Title of Invention:
- MALEATE SALTS OF A QUINAZOLINE DERIVATIVE USEFUL AS AN ANTIANGIOGENIC AGENT
- French Title of Invention:
- SELS DE MALEATE D'UN DERIVE DE QUINAZOLINE UTILE COMME AGENT ANTIANIOGENIQUE
- German Title of Invention:
- ALS ANTIANGIOGENE MITTEL GEEIGNETE MALEATSALZE EINES CHINAZOLINDERIVATS
- SPC Number:
Dates
- Filing date:
- 18/12/2004
- Grant date:
- 23/06/2010
- EP Publication Date:
- 23/06/2010
- PCT Publication Date:
- 07/07/2005
- Claims Translation Received Date:
- Translations Received Date (B1 EP Publication):
- Translations Received Date (B2 EP Publication):
- Translations Received Date (B3 EP Publication):
- Publication date:
- 13/09/2006
- EP B1 Publication Date:
- 23/06/2010
- EP B2 Publication Date:
- EP B3 Publication Date:
- Lapsed date:
- Expiration date:
- 18/12/2024
- Renunciation date:
- Revocation date:
- Annulment date:
Owner
- From:
- 18/12/2004
- Name:
- AstraZeneca AB
- Address:
- -, 151 85 Södertälje, Sweden (SE)
Agent
- Name:
- VAN MALDEREN JOELLE
- From:
- 29/07/2010
- Address:
- ROUTE D'ARLON 261, 8002, STRASSEN, Luxembourg (LU)
- To:
Inventor
- Name:
- McCABE James
- Address:
- United Kingdom (GB)
Priority
- Priority Number:
- 0330002
- Priority Date:
- 24/12/2003
- Priority Country:
- United Kingdom (GB)
Classification
- Main IPC Class:
- C07D 403/12;
Annual Fees
- Annual Fee Due Date:
- Annual Fee Number:
- Expected Payer:
- Last Annual Fee Payment Date:
- 14/12/2023
- Last Annual Fee Paid Number:
- 20
- Last Annual Fee Paid Amount:
- 300 Euro
- Payer:
- CPA GLOBAL THE IP PLATFORM
| Filing date | Document type | Number of pages |
|---|